BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230911
DTEND;VALUE=DATE:20230914
DTSTAMP:20260516T071227
CREATED:20230704T143300Z
LAST-MODIFIED:20230704T143518Z
UID:37419-1694390400-1694649599@www.pharmajournalist.com
SUMMARY:7th Complement-Based Drug Development Summit
DESCRIPTION:With the recent FDA approval of SYFOVRE and more decisions and approvals expected in 2023\, the Complement-Based Drug Development Summit is returning for its 7th year in a timely fashion. Be the first to view this year’s Event Guide below! \n7th Complement-Based Drug Development Summit\nSeptember 11-13\, 2023\nView Agenda \nReuniting experts across Nephrology\, Neurology\, Ophthalmology\, and Haematology\, join the leading companies showcasing the latest preclinical and clinical progress for complement-based therapeutics. \n\nWith 30+ expert speakers from: AGTC\, Alexion\, Alnylam\, Amgen\, Annexon\, Apellis – and that’s just the A’s!\nCovering more complement targets than ever before including C5aR2\, Factor Bb and Combination Therapy\, alongside an increased coverage of diseases\nFull of content for your whole team covering the most pressing challenges – from evaluating the value proposition of different fragments to target to designing clinical trials with high-risk patient populations\n\n \n​​​​View the full list of sessions and expert speakers here. \n​​​​​​This world-class speaker faculty will evaluate the entirety of the complement landscape\, from scientific understanding to strategic\, commercial intelligence. This means that no matter your role in the field\, you’ll leave with tangible insights to further develop your complement pipeline.
URL:https://www.pharmajournalist.com/event/7th-complement-based-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230912
DTEND;VALUE=DATE:20230915
DTSTAMP:20260516T071227
CREATED:20230714T121304Z
LAST-MODIFIED:20230714T121304Z
UID:37455-1694476800-1694735999@www.pharmajournalist.com
SUMMARY:LNP Characterization & Analytical Development Summit
DESCRIPTION:Fingerprinting Your LNP Drug Product Quality\, Safety\, Efficacy & Regulatory Compliance \nWith the recent breakthroughs from Verve Therapeutics\, Vertex-Arbor Bio\, and Mana.bio propelling the field of LNP technology forward at lightning speed beyond mRNA vaccines\, the LNP Characterization & Analytical Development Summit is your must-attend meeting to deep dive into the latest technologies and approaches throughout product lifecycle and strengthen your lipid nanoparticle characterization\, bioanalytical and assay development competencies. \nWith unmissable case studies from the likes of Pfizer\, Moderna\, AstraZeneca\, Ultranegyx\, Merck and SINTEF\, this is the definitive forum to benchmark and learn with the LNP community who unite for the first time. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nAnalyze LNP structure and morphology to relay into functional data and analytical practices with Ultragenyx and Pfizer\nOptimize the characterization of payloads to foresee the outcome of the LNP complex with Hopewell Therapeutics\, Beam Therapeutics and Moderna\nDevelop assays which align with mechanisms of action and portray total functionality of the LNP with NIST\, Editas Medicine and AstraZeneca\n\nDon’t miss this opportunity to supercharge your analytics\, and together with 60+ characterization and analytical scientists\, get inspiration to derive best practice\, and support next generation of therapeutics to patients with safety and efficacy. \nTo know more visit: https://ter.li/z7dmih
URL:https://www.pharmajournalist.com/event/lnp-characterization-analytical-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230912
DTEND;VALUE=DATE:20230915
DTSTAMP:20260516T071227
CREATED:20230720T121753Z
LAST-MODIFIED:20230720T121753Z
UID:37490-1694476800-1694735999@www.pharmajournalist.com
SUMMARY:3rd Rare & Genetic Kidney Disease Drug Development Summit
DESCRIPTION:Your one-stop shop to capturing industry’s most exciting developments to tackle rare & genetic kidney diseases. From evaluating real-world outcomes to uncovering underlying pathophysiology to interrogating translational models\, the 3rd Rare & Genetic Kidney Disease Drug Development Summit is uniquely positioned to give industry the opportunity to unite towards a shared goal and share strategic insights to move from bench to bedside and bring efficacious therapies to patients faster. \nTo know more visit: https://ter.li/jy2ot0
URL:https://www.pharmajournalist.com/event/3rd-rare-genetic-kidney-disease-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR